Abstract: A method of inhibiting effects of exogenous neurotoxic or neurotoxinic products in warm-blooded animals comprising administering to warm-blooded animals before exposure to said products an inhibitorily effective amount of reversible cholinesterase inhibitor selected from the group consisting of pyridostigmine and physostigmine followed by administration of an inhibitorily effective amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form.

Abstract: The invention relates to compounds of the following general formula (I): in which: R1 and R2 represent a hydrogen atom, or form a ring, especially a benzene ring, R3 represents a hydrogen atom or an alkyl group, especially a methyl group, X and Y, independently of one another, represent a carbon atom, or a heteroatom such as a sulphur atom S, or a group with the formula (a) in which R4 and R5 represent a hydrogen atom or a methyl group, or R4 and R5 form a heterocycle, and their use for the preparation of a drug intended for the treatment of pathologies associated with abnormally high concentrations of extracellular glutamate.

Abstract: The invention concerns novel phenylcyclidine derivatives with selective affinity for low affinity receptors, methods for preparing them, pharmaceutical compositions containing them and their use as protective agents for central or peripheral nervous system cells against acute or chronic degeneration, or as an anticonvulsant.

Abstract: A method of inhibiting effects of exogenous neurotoxic or neurotoxinic products in warm-blooded animals comprising administering to warm-blooded animals before exposure to said products an inhibitorily effective amount of reversible cholinesterase inhibitor selected from the group consisting of pyridostigmine and physostigmine followed by administration of an inhibitorily effective amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form.

Abstract: A method of inhibiting effects of neurotoxic products in warm-blooded animals comprising administering to warm-blooded animals an amount of 2-methyl-1-(1-piperidinyl)-1-(2-thienyl)-cyclohexane in substantially pure racemic, diastereoisomeric or enantiomeric form effect to inhibit effects of neurotropic products and mixtures of thienyl cyclohexylamine and at least one member of the group consisting of anticholinergic, anticonvulsant or cholinesterase-reactivating substances.

Abstract: Novel thienylcyclohexane derivatives of general formula (I), wherein R' is the 2-thienyl or 3-thienyl radical, R is the cyano radical or a radical of formula --C(O)A, and R2" is a saturated or unsaturated optionally cyclic hydrocarbon radical, or an aryl radical, are disclosed. Methods for preparing said compounds, and the use thereof as novel industrial products for the synthesis of thienylcyclohexyl derivatives, are also disclosed.

Abstract: The invention relates to pharmaceutical compositions for neuroprotection containing the compound (1S,2R) 1-[1-(2-thienyl)-2-alkylcyclohexyl]piperidine or (1S,2R) 1-[1-(2-furanyl)-2-alkylcyclohexyl]piperdine, or their pharmaceutically acceptable salts. The synthesis and method separation of racemic mixtures to provide pure enantiomers is presented. The compositions have use in the treatment of stroke, CNS trauma and Alzheimer's disease.

Abstract: The invention relates to substituted arylamines and heteroarylamines, their preparation process and the pharmaceutical composition containing them. Said substituted amine is in accordance with the formula: ##STR1## in which R.sup.1 and R.sup.2 are optionally substituted alkyl radicals or form with N an optionally substituted piperazine or piperidine cycle, R.sup.3 and R.sup.4 represent a hydrogen atom or an organic radical, Y represents CR.sup.6 or N and R.sup.5 is an optionally substituted benzothiophenyl, benzofuranyl or naphthyl radical.These amines can be used in pharmaceutical compositions for the treatment of nervous depression or for stimulating vigilance.

Abstract: The invention relates to pharmaceutical compositions for neuroprotection containing arylcyclohexylamines. These compositions comprise an arylcyclohexylamine in accordance with the formulas: ##STR1## in which: R.sup.1 represents ##STR2## with R.sup.4 being a hydrogen atom, a fluorine atom, an iodine atom or a methyl radical, R.sup.2 stands for a hydrogen atom, the radical OH or the radical CH.sub.3 and R.sup.3 stands for hydrogen atom or the radical CH.sub.2 R.sup.5 with R.sup.5 representing H, OH, Cl, Br or CH.sub.3 COO, provided that R.sup.2 and R.sup.3 are not both a hydrogen atom, or an addition salt to a pharmaceutically acceptable acid of said arylcyclohexylamine.